These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26653170)

  • 1. HisAK70: progress towards a vaccine against different forms of leishmaniosis.
    Domínguez-Bernal G; Horcajo P; Orden JA; Ruiz-Santa-Quiteria JA; De La Fuente R; Ordóñez-Gutiérrez L; Martínez-Rodrigo A; Mas A; Carrión J
    Parasit Vectors; 2015 Dec; 8():629. PubMed ID: 26653170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative strategy for visceral leishmaniosis control: HisAK70-Salmonella Choleraesuis-pulsed dendritic cells.
    Domínguez-Bernal G; Martínez-Rodrigo A; Mas A; Blanco MM; Orden JA; De La Fuente R; Carrión J
    Comp Immunol Microbiol Infect Dis; 2017 Oct; 54():13-19. PubMed ID: 28915996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S; Soto M; Carrión J; Alonso C; Requena JM
    Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani.
    Guha R; Das S; Ghosh J; Naskar K; Mandala A; Sundar S; Dujardin JC; Roy S
    Vaccine; 2013 Apr; 31(15):1905-15. PubMed ID: 23499564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and parasitological protection in a Leishmania infantum-macaque model vaccinated with adenovirus and the recombinant A2 antigen.
    Grimaldi G; Teva A; Porrozzi R; Pinto MA; Marchevsky RS; Rocha MG; Dutra MS; Bruña-Romero O; Fernandes AP; Gazzinelli RT
    PLoS Negl Trop Dis; 2014 Jun; 8(6):e2853. PubMed ID: 24945284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigenicity of
    Fernández L; Carrillo E; Sánchez-Sampedro L; Sánchez C; Ibarra-Meneses AV; Jimenez MA; Almeida VDA; Esteban M; Moreno J
    Front Immunol; 2018; 9():843. PubMed ID: 29740446
    [No Abstract]   [Full Text] [Related]  

  • 7. Mitigating an undesirable immune response of inherent susceptibility to cutaneous leishmaniosis in a mouse model: the role of the pathoantigenic HISA70 DNA vaccine.
    Domínguez-Bernal G; Horcajo P; Orden JA; De La Fuente R; Herrero-Gil A; Ordóñez-Gutiérrez L; Carrión J
    Vet Res; 2012 Aug; 43(1):59. PubMed ID: 22876751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strength and medium-term impact of HisAK70 immunization in dogs: Vaccine safety and biomarkers of effectiveness for ex vivo Leishmania infantum infection.
    Martínez-Rodrigo A; Mas A; Fernández-Cotrina J; Belinchón-Lorenzo S; Orden JA; Arias P; de la Fuente R; Carrión J; Domínguez-Bernal G
    Comp Immunol Microbiol Infect Dis; 2019 Aug; 65():137-143. PubMed ID: 31300103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.
    Zanin FH; Coelho EA; Tavares CA; Marques-da-Silva EA; Silva Costa MM; Rezende SA; Gazzinelli RT; Fernandes AP
    Microbes Infect; 2007 Jul; 9(9):1070-7. PubMed ID: 17644455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization with the HisAK70 DNA Vaccine Induces Resistance against
    Martínez-Rodrigo A; S Dias D; Ribeiro PAF; Roatt BM; Mas A; Carrión J; Coelho EAF; Domínguez-Bernal G
    Vaccines (Basel); 2019 Nov; 7(4):. PubMed ID: 31739549
    [No Abstract]   [Full Text] [Related]  

  • 12. Leishmaniasis: current status of vaccine development.
    Sukumaran B; Madhubala R
    Curr Mol Med; 2004 Sep; 4(6):667-79. PubMed ID: 15357215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress towards a Leishmania vaccine.
    Tabbara KS
    Saudi Med J; 2006 Jul; 27(7):942-50. PubMed ID: 16830009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice.
    Campos-Neto A; Webb JR; Greeson K; Coler RN; Skeiky YA; Reed SG
    Infect Immun; 2002 Jun; 70(6):2828-36. PubMed ID: 12010969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis.
    Walker PS; Scharton-Kersten T; Rowton ED; Hengge U; Bouloc A; Udey MC; Vogel JC
    Hum Gene Ther; 1998 Sep; 9(13):1899-907. PubMed ID: 9741428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia).
    Jayakumar A; Castilho TM; Park E; Goldsmith-Pestana K; Blackwell JM; McMahon-Pratt D
    PLoS Negl Trop Dis; 2011 Jun; 5(6):e1204. PubMed ID: 21695103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced protective efficacy of nonpathogenic recombinant leishmania tarentolae expressing cysteine proteinases combined with a sand fly salivary antigen.
    Zahedifard F; Gholami E; Taheri T; Taslimi Y; Doustdari F; Seyed N; Torkashvand F; Meneses C; Papadopoulou B; Kamhawi S; Valenzuela JG; Rafati S
    PLoS Negl Trop Dis; 2014 Mar; 8(3):e2751. PubMed ID: 24675711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transitory or long-lasting immunity to Leishmania major infection: the result of immunogenicity and multicomponent properties of histone DNA vaccines.
    Carrión J; Folgueira C; Alonso C
    Vaccine; 2008 Feb; 26(9):1155-65. PubMed ID: 18255202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immunogenicity and protective immunity of multi-epitopes DNA prime-protein  boost vaccines encoding Amastin-Kmp-11, Kmp11-Gp63 and Amastin-Gp63 against visceral leishmaniasis.
    Zhang J; He J; Li J; Zhou Q; Chen H; Zheng Z; Chen Q; Chen D; Chen J
    PLoS One; 2020; 15(3):e0230381. PubMed ID: 32176727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA immunization with the gene encoding P4 nuclease of Leishmania amazonensis protects mice against cutaneous Leishmaniasis.
    Campbell K; Diao H; Ji J; Soong L
    Infect Immun; 2003 Nov; 71(11):6270-8. PubMed ID: 14573646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.